Sixteen Combinations Withdrawn: India Returns to the Irrational FDC Problem

Article summary

The government has prohibited sixteen fixed-dose combination drugs on grounds of safety and efficacy, in a list dominated by antibiotic pairings and dermatological products. A fixed-dose combination places two or more active ingredients in a single formulation, and the regulatory distinction that matters is between rational combinations — where evidence shows the components work better together, as in tuberculosis and HIV therapy — and irrational ones, assembled for marketing convenience without clinical trial evidence for the pairing. Examples cited among the banned formulations include amoxicillin with serratiopeptidase and norfloxacin with tinidazole. The apex regulator is the Central Drugs Standard Control Organisation, acting under the Drugs and Cosmetics Act, 1940, and the Indian Council of Medical Research has repeatedly warned about irrational combinations. The action follows the landmark exercise of 2016, when hundreds of formulations were prohibited, an order that was subsequently litigated extensively. The public health stake is antimicrobial resistance: combining antibiotics without justification exposes bacterial populations to multiple agents simultaneously, accelerating resistance to both, and India's high burden of resistant infection makes withdrawal of such products one of the few supply-side levers a regulator can pull directly.